AgingResearch.NewsJoin free

Phase 1/2RecruitingAge-related condition

Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease

Sponsor
NKGen Biotech, Inc. (Industry)
Enrolment
36 planned
Conditions
Moderate Alzheimer Disease
Interventions
SNK01; Placebo
Ages
adults, older adults
Registry
NCT06189963

Full record on ClinicalTrials.gov

From the registry

The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion 2. Can SNK01 administration improve cognitive assessment scores and biomarkers

Primary outcomes

  • Number of participants with dose-limiting toxicity
  • Maximum tolerated dose determination
  • Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
  • Preliminary efficacy in cognitive assessment scores of CDR-SB

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Registered

  5. Started